FDA sends Fresenius new warning letter; P&G CEO got big boost as he exited; Statins to hold onto market;

@FiercePharma: Merck has the Zilmax PR right: Animal advocate Temple Grandin to consult on livestock drug's safety. More | Follow @FiercePharma

@EricPFierce: Regeneron takes a "byte" out of excess manufacturing capacity in Ireland. ICYMI yesterday | Follow @EricPFierce

@CarlyHFierce: Amid Purdue criticism, CVS cuts opioid access for 'risky' prescribers. ICYMI yesterday | Follow @CarlyHFierce

> Germany's Fresenius said today that it is addressing issues raised by the FDA in a warning letter about a blood bag manufacturing facility in Puerto Rico. Report

> A new study says the market for drugs to treat dyslipidemia will reach $31 billion in 2022 and that statins will remain the biggest sellers, despite work on new treatments. Story

> SBI Pharmaceuticals is striking a deal in Bahrain to open a manufacturing facility to produce diabetes and cancer drugs. Report

> The FDA is looking more closely at the accuracy of consumer blood glucose testing. Report (reg. req.)

> Lupin has gotten FDA approval to make a generic of Sanofi's ($SNY) tuberculosis drug Rifadin. Item

Medical Device News

@FierceMedDev: Bard settles vaginal mesh suit as thousands pend. ICYMI yesterday | Follow @FierceMedDev

@DamianFierce: Israel's InSightec is expanding into Canada with its surgery-free uterine fibroid treatment. News | Follow @DamianFierce

@MarkHFierce: We're launching a new diagnostics report in less than a week, and I'll be writing it. Sign up here | Follow @MarkHFierce

@MichaelGFierce: FDA clears Novo Nordisk's insulin injection pen for children. Item | Follow @MichaelGFierce

> FDA's guidance for wireless devices sparks business opportunity. More

> KKR, Bain said to bid for Panasonic's billion-dollar health unit. Article

> A first: Medtronic co-founder absent from annual meeting. Item

Biotech News

@FierceBiotech: Shire and Santaris extend their strategic alliance to discover, develop LNA-drugs in the rare disease field. Press release | Follow @FierceBiotech

@JohnCFierce: The latest on the Onyx buyout: Yes they are. No they aren't. Say what? Item | Follow @JohnCFierce

@EmilyMFierce: This week's career moves in biopharma. Chutes & Ladders | Follow @EmilyMFierce

> GlaxoSmithKline ponders future of Crohn's disease drug after PhIII flop. Report

> 3-D printing creates living tissue cells, holds promise for medical research. Story

> Vical restructures, chops 47 jobs after PhIII immunotherapy flop. Article

> Mystery doc cited for handing insider trial info to SAC trader. Report

And Finally... Procter & Gamble ($PG), which has a significant OTC joint venture with Teva Pharmaceutical Industries ($TEVA), today acknowledged paying a $3.3 million bonus in 2013 to former CEO Bob McDonald, who stepped down in May amid disappointing sales by the company. Report